Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Increases Proposed Offering of Stock to $50M

NEW YORK (GenomeWeb News) – Cancer Genetics today increased the proposed amount it is seeking to raise from a public offering of its common stock.

In an amended Form S-1, the Rutherford, NJ-based cancer diagnostics firm said that it plans to offer $50 million of its common shares. When the company announced the offering earlier this month, it said that the proposed maximum aggregate offering price would be $46 million.

The company has not said how many shares it plans to offer.

Aegis Capital is the sole book-running manager, and Feltl & Co., Cantor Fitzgerald, and Dougherty & Co., are co-managers on the offering. Cancer Genetics is granting the underwriters a 45-day option to purchase up to $7.5 million of additional shares of its common stock to cover any overallotments, which could potentially bring the total amount raised to $57.5 million.

It said that net proceeds from the offering are expected to be about $45.9 million, or $52.9 million if the underwriters exercise their overallotment option in full.

Cancer Genetics made a public offering of $15 million of its shares in August, when it also began trading on the Nasdaq. The company went public in April.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.